Connect your AI

Pfizer PFE Cumulative amount of fair value hedging adjustment

Cumulative amount of fair value hedging adjustment at other companies

Merck & Co.MRK

——

Other financials

Income statement

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+5.0%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

Market cap$143.68B+11.1%

Enterprise value$206.35B+9.2%

P/E11.9×—

P/S2.3×+0.2×

Profitability

Gross margin73.5%+1.2pp

Net margin15.7%—

Returns & leverage

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's cumulative amount of fair value hedging adjustment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pfizer's cumulative amount of fair value hedging adjustment?: Pfizer (PFE) reported cumulative amount of fair value hedging adjustment of -$248M in Q1 2026.